These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 25844817)
1. Cowpox Helped Against Smallpox; Will the Goat Lentivirus (Caprine Arthritis Encephalitis Virus) Help Against HIV-1? Chebloune Y; Moussa M; Arrode-Brusés G; Gagnon J AIDS Res Hum Retroviruses; 2015 Jun; 31(6):577-8. PubMed ID: 25844817 [No Abstract] [Full Text] [Related]
2. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques. Smith JM; Amara RR; McClure HM; Patel M; Sharma S; Yi H; Chennareddi L; Herndon JG; Butera ST; Heneine W; Ellenberger DL; Parekh B; Earl PL; Wyatt LS; Moss B; Robinson HL AIDS Res Hum Retroviruses; 2004 Jun; 20(6):654-65. PubMed ID: 15242543 [TBL] [Abstract][Full Text] [Related]
3. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection. Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828 [TBL] [Abstract][Full Text] [Related]
5. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963 [TBL] [Abstract][Full Text] [Related]
6. A novel non-integrative single-cycle chimeric HIV lentivector DNA vaccine. Moussa M; Arrode-Brusés G; Manoylov I; Malogolovkin A; Mompelat D; Ishimwe H; Smaoune A; Ouzrout B; Gagnon J; Chebloune Y Vaccine; 2015 May; 33(19):2273-2282. PubMed ID: 25825333 [TBL] [Abstract][Full Text] [Related]
7. HIV-1 neutralizing antibodies: how full is the bottle? Moore JP; Burton DR Nat Med; 1999 Feb; 5(2):142-4. PubMed ID: 9930854 [No Abstract] [Full Text] [Related]
8. Use of lentivirus-like particles alone and in combination with live vaccinia-virus-based vaccines. Panicali DL; Mazzara G; Sullivan JL; Hesselton R; Shen L; Letvin N; Daniel M; Desrosiers R; Stott EJ AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1449. PubMed ID: 1466979 [No Abstract] [Full Text] [Related]
9. Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component. Wyatt LS; Earl PL; Liu JY; Smith JM; Montefiori DC; Robinson HL; Moss B AIDS Res Hum Retroviruses; 2004 Jun; 20(6):645-53. PubMed ID: 15242542 [TBL] [Abstract][Full Text] [Related]
10. Studies in macaques on cross-clade T cell responses elicited by a DNA/MVA AIDS vaccine, better conservation of CD8 than CD4 T cell responses. Smith JM; Amara RR; Wyatt LS; Ellenberger DL; Li B; Herndon JG; Patel M; Sharma S; Chennareddi L; Butera S; McNicholl J; McClure HM; Moss B; Robinson HL AIDS Res Hum Retroviruses; 2005 Feb; 21(2):140-4. PubMed ID: 15725752 [TBL] [Abstract][Full Text] [Related]
11. DNA vaccines against human immunodeficiency virus type 1. Estcourt MJ; McMichael AJ; Hanke T Immunol Rev; 2004 Jun; 199():144-55. PubMed ID: 15233732 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of a lentiviral-based DNA vaccine driven by the 5'LTR of the naturally attenuated caprine arthritis encephalitis virus (CAEV) in mice and macaques. Arrode-Brusés G; Hegde R; Jin Y; Liu Z; Narayan O; Chebloune Y Vaccine; 2012 Apr; 30(19):2956-62. PubMed ID: 22387218 [TBL] [Abstract][Full Text] [Related]
13. Towards an HIV-1 vaccine: lessons from studies in macaque models. Hulskotte EG; Geretti AM; Osterhaus AD Vaccine; 1998; 16(9-10):904-15. PubMed ID: 9682336 [TBL] [Abstract][Full Text] [Related]
14. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868 [TBL] [Abstract][Full Text] [Related]
15. Cross-reactivity between caprine arthritis-encephalitis virus and type 1 human immunodeficiency virus. Tesoro-Cruz E; Hernández-González R; Kretschmer-Schmid R; Aguilar-Setién A Arch Med Res; 2003; 34(5):362-6. PubMed ID: 14602501 [TBL] [Abstract][Full Text] [Related]
16. DermaVir, a novel HIV immunisation technology. Lori F; Trocio J; Bakare N; Kelly LM; Lisziewicz J Vaccine; 2005 Mar; 23(17-18):2030-4. PubMed ID: 15755566 [TBL] [Abstract][Full Text] [Related]
18. Immunodominant antigenic sites in primate immunodeficiency viruses and in vivo protection. Norrby E; Putkonen P; Albert J; Fenyö EM Biotechnol Ther; 1991; 2(1-2):21-9. PubMed ID: 1668984 [No Abstract] [Full Text] [Related]
19. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma. Gómez CE; Abaitua F; Rodríguez D; Esteban M Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077 [TBL] [Abstract][Full Text] [Related]